Arcus Biosciences Inc (RCUS)
15.24
-0.32
(-2.06%)
USD |
NYSE |
May 08, 16:00
15.24
0.00 (0.00%)
After-Hours: 17:55
Arcus Biosciences Cash from Investing (Quarterly): 28.00M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.00M |
| September 30, 2023 | 11.00M |
| June 30, 2023 | 26.00M |
| March 31, 2023 | 129.00M |
| December 31, 2022 | 47.00M |
| September 30, 2022 | 23.00M |
| June 30, 2022 | -215.00M |
| March 31, 2022 | -268.00M |
| December 31, 2021 | 18.78M |
| September 30, 2021 | -88.61M |
| June 30, 2021 | 3.003M |
| March 31, 2021 | 62.83M |
| December 31, 2020 | 0.136M |
| September 30, 2020 | -387.12M |
| Date | Value |
|---|---|
| June 30, 2020 | -87.07M |
| March 31, 2020 | 40.06M |
| December 31, 2019 | -12.10M |
| September 30, 2019 | 30.36M |
| June 30, 2019 | 26.67M |
| March 31, 2019 | 14.28M |
| December 31, 2018 | 2.511M |
| September 30, 2018 | -83.34M |
| June 30, 2018 | -16.12M |
| March 31, 2018 | -16.49M |
| December 31, 2017 | -42.07M |
| September 30, 2017 | 12.73M |
| June 30, 2017 | -3.243M |
| March 31, 2017 | -16.49M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-387.12M
Minimum
Sep 2020
129.00M
Maximum
Mar 2023
-32.21M
Average
18.78M
Median
Dec 2021
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences Inc | -2.207B |
| Catalyst Pharmaceuticals Inc | -38.32M |
| Integra Lifesciences Holdings Corp | -53.96M |
| Vertex Pharmaceuticals Inc | -886.50M |
| Adverum Biotechnologies Inc | -9.878M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -88.00M |
| Cash from Financing (Quarterly) | 3.00M |
| Free Cash Flow | -330.00M |
| Free Cash Flow Per Share (Quarterly) | -1.25 |
| Free Cash Flow to Equity (Quarterly) | -94.00M |
| Free Cash Flow to Firm (Quarterly) | -94.00M |
| Free Cash Flow Yield | -29.26% |